StreetInsider.com News Articles

Form SCHEDULE 13G/A Caris Life Sciences, Filed by: J H Whitney VI L P

Wed, 12 Aug 2026 12:38:00 -0400

si-local-file:///var/storage/secattach/20260812/26911436.html

Form SCHEDULE 13G/A Caris Life Sciences, Filed by: J H Whitney VI L P

Wed, 12 Aug 2026 12:38:00 -0400

si-local-file:///var/storage/secattach/20260812/26911436.html

Form 144 Caris Life Sciences, Filed by: POSTE GEORGE

Fri, 07 Aug 2026 17:12:00 -0400

si-local-file:///var/storage/secattach/20260807/26892169.html

Form 144 Caris Life Sciences, Filed by: POSTE GEORGE

Fri, 07 Aug 2026 17:12:00 -0400

si-local-file:///var/storage/secattach/20260807/26892169.html

Form SCHEDULE 13G/A Caris Life Sciences, Filed by: TSSP Sub-Fund HoldCo LLC

Fri, 07 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260807/26891518.html

Form SCHEDULE 13G/A Caris Life Sciences, Filed by: TSSP Sub-Fund HoldCo LLC

Fri, 07 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260807/26891518.html

Form 10-Q Caris Life Sciences, For: Jun 30

Wed, 05 Aug 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260805/26875637.html

Form 10-Q Caris Life Sciences, For: Jun 30

Wed, 05 Aug 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260805/26875637.html

CAI International (CAI) Misses Q2 EPS by 1c, Revenue Beats, Offers Guidance

Wed, 05 Aug 2026 16:50:38 -0400

CAI International (NASDAQ: CAI) reported Q2 EPS of $0.00, $0.01 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $263.7 million versus the consensus estimate of $238 million.

GUIDANCE:

CAI International sees FY2026 revenue of $1.03-1.04 billion, versus the consensus of $1 billion.

For earnings history and earnings-related data on CAI International (CAI) click here.

CAI International (CAI) Misses Q2 EPS by 1c, Revenue Beats, Offers Guidance

Wed, 05 Aug 2026 16:50:38 -0400

GUIDANCE:

CAI International sees FY2026 revenue of $1.03-1.04 billion, versus the consensus of $1 billion.

For earnings history and earnings-related data on CAI International (CAI) click here.

Form 8-K Caris Life Sciences, For: Aug 05

Wed, 05 Aug 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260805/26874466.html

Form 8-K Caris Life Sciences, For: Aug 05

Wed, 05 Aug 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260805/26874466.html

Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

Wed, 05 Aug 2026 16:05:00 -0400

Revenue growth of 45% driven by strong performance in molecular profiling services, including approximately 59,200 clinical cases, consisting of over 114,000 whole exome/whole transcriptome tests with over 345,000 total oncology tests

Raises 2026 revenue guidance to $1.03 to $1.04 billion, representing growth of 27% to 28%

IRVING, Texas, Aug. 5, 2026 /PRNewswire/ -- Caris Life Sciences, Inc. (Nasdaq: CAI), a leading TechBio company actively developing and commercializing solutions to transform healthcare, today reported financial results for the quarter ended June 30, 2026.

Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

Wed, 05 Aug 2026 16:05:00 -0400

Raises 2026 revenue guidance to $1.03 to $1.04 billion, representing growth of 27% to 28%

Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

Wed, 05 Aug 2026 16:05:00 -0400

Raises 2026 revenue guidance to $1.03 to $1.04 billion, representing growth of 27% to 28%

Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

Wed, 05 Aug 2026 16:05:00 -0400

Raises 2026 revenue guidance to $1.03 to $1.04 billion, representing growth of 27% to 28%

Form 144 Caris Life Sciences, Filed by: POSTE GEORGE

Mon, 03 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260803/26857915.html

Form 144 Caris Life Sciences, Filed by: POSTE GEORGE

Mon, 03 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260803/26857915.html

Citi Assumes Caris Life Sciences Inc (CAI) at Buy

Thu, 30 Jul 2026 10:02:57 -0400

Citi analyst Brendan Digan assumes coverage on Caris Life Sciences Inc (NASDAQ: CAI) with a Buy rating and a price target of $28.00.

For an analyst ratings summary and ratings history on Caris Life Sciences Inc click here. For more ratings news on Caris Life Sciences Inc click here.

Shares of Caris Life Sciences Inc closed at $15.59 yesterday.

Caris Life Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026

Thu, 16 Jul 2026 08:30:00 -0400

IRVING, Texas, July 16, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading TechBio company, today announced it will report second quarter 2026 financial results on Wednesday, August 5, 2026.

Caris Life Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026

Thu, 16 Jul 2026 08:30:00 -0400

Caris Life Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026

Thu, 16 Jul 2026 08:30:00 -0400

Caris Life Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026

Thu, 16 Jul 2026 08:30:00 -0400

Caris Life Sciences to offer PTEN IHC testing for prostate cancer

Tue, 14 Jul 2026 08:31:59 -0400

Caris Life Sciences (NASDAQ: CAI) announced it will offer in-house PTEN immunohistochemistry (IHC) testing following the FDA approval of capivasertib, in combination with abiraterone and prednisone, for adults with PTEN-deficient metastatic androgen pathway modulation-naïve or -sensitive prostate cancer.

The testing is designed to identify patients whose tumors exhibit PTEN protein loss, a molecular alteration associated with activation of the PI3K/AKT pathway. According to the company, one in four patients with this form of prostate cancer have PTEN-deficient tumors. Prostate cancer accounts for more than 300,000 new diagnoses annually in the United States.

Testing will be performed within Caris' CAP-accredited, CLIA-certified laboratories. The

Caris Life Sciences Expands Precision Oncology in Metastatic Prostate Cancer with PTEN IHC Testing

Tue, 14 Jul 2026 08:30:00 -0400

IRVING, Texas, July 14, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced it will offer in-house PTEN immunohistochemistry (IHC) testing following the recent FDA approval of a biomarker-guided therapy and companion diagnostic assay. This testing is designed to help identify patients with PTEN-deficient metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer (previously known as metastatic hormone-sensitive prostate cancer) who are eligible for the newly approved biomarker-guided therapy, representing a significant advancement in precision